[{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis Recruits Individuals with Muscle Atrophy for Phase 1\/2a Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis\u2019 Phase 1\/2a Clinical Trial Approved by Data Safety and Monitoring Board to Proceed with Dose Escalation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Toray Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Immunis \/ Immunis"},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunis Partners with Springbok Analytics to Assess IMMUNA for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":"13","companyTruncated":"Immunis \/ Springbok"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Clearance for Immunis\u2019 Phase II Sarcopenic Obesity Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Immunis \/ Not Applicable"}]